

## Ikonisys: Hospitex Expands in Ukraine through a Partnership with Diagen LLC to Fight Cancer

Paris, France – May 21, 2024 – 6:00 pm CEST – Ikonisys SA (Euronext Growth Paris: ALIKO), a company specializing in the early and accurate detection of cancers through a unique, fully automated solution for medical analysis laboratories, today announces that Hospitex has signed a new distribution partnership in Ukraine with Diagen LLC, a leading Ukrainian distributor and laboratory services provider. This collaboration aims at reinforcing the Company's commitment to the global fight against cancer.

Despite the challenging environment amidst the war, this strategic alliance represents a significant step in Hospitex's mission to enhance the accessibility of advanced cancer diagnostic tools and treatments and make innovative healthcare solutions available to those who need them most. The market for cytology in Ukraine is substantial with a growing emphasis on early cancer detection and preventive healthcare. Urinary cytology is also becoming more significant, with thousands of tests performed each year to diagnose and monitor urinary tract cancers. By introducing Hospitex's advanced diagnostic products into this market, the aim is to significantly enhance the accuracy and efficiency of critical tests.

In the framework of this partnership, Diagen LLC will both distribute Hospitex's cutting-edge technologies and use them in its own laboratory, particularly for Pap smear tests and urinary cytology. Thanks to Hospitex's expertise, Diagen LLC will enable Ukrainian healthcare professionals to have access to reliable and precise diagnostic tools.

*"Partnering with Diagen LLC in Ukraine during such tumultuous times is a testament to our dedication to the global fight against cancer and its spread worldwide", said Francesco Trisolini, CEO of Hospitex. "We believe that every patient, regardless of their circumstances, deserves the best possible care. This initiative once again demonstrates our commitment to supporting healthcare systems and providing crucial medical supplies where they are most needed. Our new distributor and partner, Diagen LLC, shares our vision and commitment to improving healthcare outcomes. Together, we will focus on ensuring that even amidst adversity, the fight against cancer continues unabated."*

The first delivery to Diagen LLC has recently been recorded contributing to H1 2024 Hospitex's revenue. The next phase of this collaboration consists into introducing Ikonisys' products into the Ukrainian market, further enhancing diagnostic capabilities and patient care.

**Mario Crovetto, CEO of Ikonisys,** declares: *"We are thrilled to announce this new milestone as our ambition to contribute to the fight against cancer globally is very high. We look forward to providing active support to this territory in the midst of conflict and improve the lives of the population in need there."*

This collaboration is part of Hospitex's and Ikonisys' broader strategy to expand their global footprint and provide essential medical technology to underserved regions. By enhancing their distribution network, the Companies are taking proactive steps to address the global burden of cancer, delivering hope and improved health outcomes to communities in need.

### About Hospitex International

Hospitex International is the world leading company for cytology standardized monolayer preparations. With CYTOfast it has re-invented the cytological diagnostics. Hospitex offers a full range of integrated solutions aimed at streamlining diagnostic processes in cytology. The global shortage of expertise in pathology requires tools and technologies that enable diagnostic safety, efficiency and capacity building. In this area, Hospitex is recognized as the precision diagnostics player in cytology.

For more information: <https://www.hospitex.com/en/>

### Contact

---

#### Hospitex International

Marco Testini

Investor Relations

[marco.testini@hospitex.com](mailto:marco.testini@hospitex.com)

### About Ikonisys

Ikonisys SA is a cell-based diagnostics company based in Paris (France), New Haven (Connecticut, USA) and Milan (Italy) specialized in the early and accurate detection of cancer. The company develops, produces and markets the proprietary Ikoniscope20® and Ikoniscope20max® platforms, fully-automated solutions designed to deliver accurate and reliable detection and analysis of rare and very rare cells. Ikonisys has received FDA clearance for several automated diagnostic applications, which are also marketed in Europe under CE certification. Through its breakthrough fluorescence microscopy platform, the company continues to develop a stream of new tests, including liquid biopsy tests based on Circulating Tumor Cells (CTC).

For further information, please go to [www.ikonisys-finance.com](http://www.ikonisys-finance.com)

### Contacts

---

#### Ikonisys

Alessandro Mauri

CFO

[investors@ikonisys.com](mailto:investors@ikonisys.com)

#### NewCap

Louis-Victor Delouvrier/Aur lie Manavarere

Investor Relations

[ikonisys@newcap.eu](mailto:ikonisys@newcap.eu)

Tel.: +33 (0)1 44 71 94 94

#### NewCap

Nicolas Merigeau

Media Relations

[ikonisys@newcap.eu](mailto:ikonisys@newcap.eu)

Tel.: +33 (0)1 44 71 94 98

### Disclaimer

This press release contains forward-looking statements about the Company's prospects and development. These statements are sometimes identified by the use of the future tense, the conditional tense and forward-looking words such as "believe", "aim to", "expect", "intend", "estimate", "believe", "should", "could", "would" or "will" or, where appropriate, the negative of these terms or any other similar variants or expressions. This information is not historical data and should not be construed as a guarantee that the facts and data set forth will occur. This information is based on data, assumptions and estimates considered reasonable by the Company. It is subject to change or modification due to uncertainties relating to the economic, financial, competitive and regulatory environment. This information contains data relating to the Company's intentions, estimates and objectives concerning, in particular, the market, strategy, growth, results, financial situation and cash flow of the Company. The forward-looking information contained in this press release is made only as of the date of this press release. The Company does not undertake to update any forward-looking information contained in this press release, except as required by applicable law or regulation. The Company operates in a competitive and rapidly changing environment and therefore cannot anticipate all of the risks, uncertainties or other factors that may affect its business, their potential impact on its business or the extent to which the materialization of any one risk or combination of risks could cause results to differ materially from those expressed in any forward-looking information, it being recalled that none of this forward-looking information constitutes a guarantee of actual results.